An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia [EXTENSION OF 700245233]
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Burosumab (Primary)
- Indications X-linked dominant hypophosphataemic rickets
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 15 Sep 2014 Results published in the Media Release and presented at the American Society of Bone and Mineral Research (ASBMR) Annual Meeting.
- 01 Sep 2014 Status changed from active, no longer recruiting to completed.
- 30 May 2014 New trial record